Decreases in the Disease Activity Score in 28 joints using the C-reactive protein level ( DAS28-CRP ) , Clinical Disease Activity Index ( CDAI ) , and CRP level from baseline were observed at week 12 in the ixekizumab groups in both populations ( P < 0.05 versus placebo ) .